(Q36523502)

14 August 2017

1 reference

title

Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients (English)

1 reference

14 August 2017

5

Clinton F Stewart

1 reference

14 August 2017

4

Wayne L Furman

1 reference

14 August 2017

Burgess B Freeman

1

1 reference

14 August 2017

Najat C Daw

series ordinal

2

1 reference

14 August 2017

J Russell Geyer

series ordinal

3

1 reference

14 August 2017

publication date

1 April 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

310-317

1 reference

The ErbB signaling network: receptor heterodimerization in development and cancer

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Growth factor signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

EGF receptor in neoplasia and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Expression of constitutively activated EGFRvIII in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Development of inhibitors for protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

The epidermal growth factor receptor as a target for colorectal cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Growth factors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Genetic alterations in pediatric high-grade astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600632058

10.1080/07357900600632058

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference